Yorke Justin W's Form 4 filing

Processa Pharmaceuticals, Inc. (PCSA) · filed Dec 7, 2021

Accession no.: 0001567619-21-021710
Filed: Dec 7, 2021
Trade date: Dec 3-6, 2021
Filing delay: 4 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $46.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Yorke Justin WCIK 0001361896	Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Dec 3, 2021	Common Stock	SSaleDisposed	−5,500	$4.84^F1	−$26,620	538,617	Indirect
Dec 6, 2021	Common Stock	SSaleDisposed	−4,200	$4.71^F2	−$19,782	534,417	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8001 to $5.01, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.5601 to $4.80, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)